Trader's STOCK ALERTS

Attention Traders...OTCBB CBIS

WEB SITE / STOCKWATCH / YAHOO / BLOOMBERG / PINK SHEET / DEUTCHE INVESTOREN

Dr. Roscoe M. Moore Jr., U.S. Assistant Surgeon General (Retired), Appointed to Cannabis Science Scientific Advisory Board

Dr. Robert Melamede, President and CEO of Cannabis Science (CBIS), announced today that Roscoe Moore, DVM, PhD, MPH has been appointed to the Scientific Advisory Board.

About Dr Roscoe M. Moore Jr., DVM, MPH, Ph.D.,
Senior Scientific Advisory Board Member, CBIS

Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA) along with the positions in the US Public Health Service, and most recently, the Office of the US Secretary of Health and Human Services.

Dr. Moore was named a Senior Fellow at the Potomic Institute in June 2003. He is currently the CEO and Vice Chairman of the Global Flu Consortium. As both a distinguished epidemiologist and veterinarian, Dr. Moore is particularly well positioned to help guide business planning and response to the Avian Flu. Dr. Moore brings to the Institute, deep experience and leadership through service that includes responsibilities as former Assistant United States Surgeon General, and as Rear Admiral in the U.S. Public Health Service. One of the world-renowned experts in epidemiology, Dr. Moore has been involved in the surveillance of emerging and re-emerging diseases worldwide as well as bioterrorism issues, and the safety of bioengineered foods.

Dr. Moore was the top-ranking veterinarian in all of the Uniformed Services, and served as the Associate Director for Development Support and African Affairs for the Department of Health and Human Services (HHS). In this capacity, Dr. Moore was the principal liaison between HHS and ministries of health for 53 countries in Africa, focusing on developing infrastructure and technical support to deliver preventive and curative human health needs for the continent.

Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; he also has received an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues.

“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining the Cannabis Science Scientific Advisory Board as the company enters into further clinical development of a wide range of commercial clinical investigations. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to Cannabis Science. In addition to overseeing the development of CS-TATI-1, he will assist in our path towards human studies for HIV drug resistance and catabolic cachexia,” commented Dr Melamede. “Dr. Moore’s decision to join Cannabis Science's Scientific Advisory Board emphasizes the potential of phytocannabinod antiviral activity and our strong research and development efforts.”

CS-TATI-1 is in preclinical development intended to target HIV TAT, which is an important target for developing new HIV drugs, which are urgently needed. While there are currently 30 antiretroviral drugs on the market, increasing drug resistance to and toxicity from long term use of all existing medications. There is a high demand and need for new treatments to treat HIV drug resistance patients

Cannabis Science at AIDS 2012

AIDS 2012 is said to be the largest AIDS conference to date, with over 30,000 participants coming together from 200 different countries, Cannabis Science will be presenting at the World AIDS Institute’s Treatment Horizons satellite symposium on Cannabis Science’s HIV therapeutic research program based on the recent discovery by the Mount Sinai School of Medicine that phytocannabinoids inhibit a key HIV gene called TAT, which controls the virus’s ability to replicate.

Cannabis Science is also currently working with CBR International Corp. to develop a pre-IND application to the FDA that focuses on the use of CS-S/BCC-1 cannabinoid-based topical preparations for the treatment of basal and squamous cell carcinomas. CBR International’s Regulatory Strategy and Affairs Group are experienced in developing strategies for companies to proceed through various regulatory pathways to market in the United States and Europe. Their diverse team has the expertise in drugs, biologics and devices to efficiently navigate the regulatory approval process. They have Prepared and submitted over 100 INDs, IND, amendments, IDEs and Annual Reports to FDA. CBR has also Planned and participated in over 20 pre-IND/Pre-IDE meetings with FDA. As well, developed and implemented programs to prepare sponsors for Type A, B, and C meetings with FDA.

Cannabis Science released a press release dated June 5, 2012, titled “Cannabis Science Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development” which, is featured on the AIDS 2012 Reunion Website: http://www.aids2012reunion.org/

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Provides Update on Its “Trimcare Brand” Acquisition

Cannabis Science, Inc. (CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis-based products, is pleased to provide an update on its recent acquisition of the “Trimcare Brand”. Cannabis previously announced the acquisition on June 11, 2012.

Since that time, while further reviewing the agreements, both parties realized that due to some legal issues regarding licensing and ownership of certain assets the agreements need to be re-drafted.

The parties are currently working with the attorney’s on revising the finalized documents and once the documents are finalized, Cannabis will make its filings with the S.E.C. disclosing the acquisition.

Dr. Ivan Goldsmith has provided 20 years of professional service within the Las Vegas community. Trimcare has 5,000 active patients consisting of in and out of state patients, who are being treated by internal medicine, bariatrics, and anti-aging methods. Trimcare is a premier integrated weight loss and anti-aging clinic in Las Vegas. Also providing a number of additional services such as a “Physician Dispensing Pharmacy”. Cannabis Science comes together with Goldsmith Heath Care, in plans to expand the Trimcare line across the US in every major metropolis. These plans consist of opening up a second, third and fourth location in Las Vegas. Cannabis Science is currently in negotiations to open up the second clinic, in Henderson, Las Vegas. The first clinic already resides at 4240 West Flamingo Rd in Las Vegas and is 5,000 square feet.

Dr. Ivan Goldsmith and his staff will continue to work with Cannabis Science immensely. In addition to expanding operations, the Companies will combine their formulations along with medical cannabis to bring together a new line of products, ranging from all areas of medical and cosmetic needs. Trimcare is active in alternative delivery methods such as creams, pellets, patches, and transdermal skin delivery systems. Trimcare currently has 30 over-the-counter products on the market. Making up these product lines are supplements, skin care products, food, and hormone products. From inception, manufacturing, commercialization, relationships and products, Dr. Goldsmith has brought these 30 products to the market himself, and Cannabis Science plans to use his expertise and integrate them into its future line of products as well.

Cannabis Science will add many new additions to its team within its Executive Management, Scientific Advisory Board and Policy Advisory Board, including Trimcare employees, will have almost 30 staff members ranging from a wide variety of expertise.

For further information about Trimcare and Dr. Ivan Goldsmith, you can go to the Trimcare website, www.trimcare.com or read the previous news release on the Cannabis Science website www.cannabisscience.com, dated May 3, 2012 or click this link, http://www.cannabisscience.com/news-a-media/press-releases/292-cannabis-science-teams-with-dr-ivan-goldsmith-of-trimcare-in-las-vegas-for-innovative-weight-loss-programs-based-on-research-of-the-endocannabinoid-system.html.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements